EU Pharmaceutical Package - EU Pharmaceutical Legislative Reform and its Impact on Türkiye
EU Pharmaceutical Package - EU Pharmaceutical Legislative Reform and its Impact on Türkiye
Publication | Update:
Jun 2024
On 26 April 2023, the European Commission (the “Commission”) adopted a proposal for a new Directive and Regulation (the “Proposal”) which revise and replace the existing general pharmaceutical legislation.
The proposal adopted by the Commission replaces the existing general pharmaceutical legislation (Regulation 726/2004 and Directive 2001/83/EC) and the legislation on pharmaceuticals for children and rare diseases (Regulation 1901/2006 and Regulation 141/2000/EC respectively).
In the Commission’s press release on the Proposal, it was stated that the pharmaceuticals authorized in the EU are still not reaching patients fast enough and are not equally accessible across all Member States. The proposal aims to prevent pharmaceutical shortages and unmet medical needs due to high pricing of innovative treatments. In addition to addressing public health from a pharmaceutical access viewpoint, the proposal aims to adapt the rules to new technologies, reduce bureaucracy, and simplify marketing authorisation procedures for pharmaceutical products to ensure that the EU remains an attractive place for pharmaceutical investment and a world leader in the development of pharmaceuticals.
The revisions aim to achieve the following main objectives in particular:
- Establish a single market for pharmaceuticals to make sure all patients across the EU have timely and equitable access to safe, effective, and affordable pharmaceuticals;
- Continue to offer an attractive and innovation-friendly environment for research, development, and production of pharmaceuticals in Europe;
- Significantly reduce the administrative burden by considerably expediting procedures, and decrease the time required for pharmaceuticals’ authorisation, enabling them to reach patients faster;
- Improve the availability of pharmaceuticals and ensure their availability to patients regardless of where they live in the EU through strict reporting systems on critical shortages of pharmaceuticals;
- Address antimicrobial resistance (AMR) and the presence of pharmaceuticals in the environment through a One Health approach in the world and EU;
- Make pharmaceuticals more environmentally sustainable.
- To achieve these objectives, the Proposal includes amendments regarding the entire lifecycle of pharmaceuticals. In this context, the Proposal includes the following amendments to incentivise pharmaceutical companies, especially regarding innovation:
- Encouraging comparative clinical research to develop pharmaceuticals to address unmet medical needs;
- Create an incentive system that rewards companies that develop pharmaceuticals that can cure irreversible diseases;
- Reconsidering market exclusivity for pharmaceuticals used to treat rare diseases and ensuring the availability of generics and biosimilars;
- Speeding up the marketing authorisation process for new pharmaceuticals, for example, by reducing the EMA’s review period from 210 days to 180 days and reducing the Commission’s approval period from 67 days to 46 days.
In addition, the Commission proposes reducing the current standard protection period for data exclusivity from 8 years to 6 years, with various possibilities for extension. This period may be extended by 2 years if the medicinal product is marketed in all 27 Member States, 6 months if the medicinal product fulfils an unmet medical need, 6 months if comparative clinical trials are conducted, and 1 year if the medicinal product has a new therapeutic indication. These provisions, which reduce the duration of data exclusivity, have been criticised by many institutions and organizations, notably the EFPIA (European Federation of Pharmaceutical Industries and Associations). It is argued that the Proposal reduces R&D incentives, contrary to what was announced, by stating that the criterion that the pharmaceuticals should be marketed in 27 countries is not always under the control of pharmaceutical companies and requires significant investment, in addition to the criteria on comparative clinical research and unmet medical needs failing to suffice in terms of the incentives they offer in relation to the costs and time incurred to achieve the objectives, and having narrow, unpredictable success criteria. In this light the Proposal appears to reduce R&D incentives, contrary to what has been announced. The reduction of the standard protection period for data exclusivity to 6 years is also of interest for Türkiye. Indeed, the Commission’s 2023 Türkiye report states that “Even though Türkiye has in place a regulatory data protection regime since 2005, the scope is limited and excludes biologics and combination products. The length is also limited, reducing the effective protection period in Türkiye.”
Finally, the Proposal also proposes some amendments to the Bolar Exemption provision. Under the current regulation, the scope of the Bolar Exemption includes only acts for the purposes of obtaining marketing authorisation by generic manufacturers. The proposal stipulates a broadening of the exemption to include studies and trials to generate data for Health Technology Assessments (HTA), the pricing and reimbursement process, and activities necessary for these purposes, including by third parties. This proposal has been criticised on the grounds that generics are not obliged to produce any data for HTA or price and reimbursement. Additionally the concept of patent linkage, akin to patent-authorisation connection in the US, does not exist in the EU, requiring patent holders to consider price and reimbursement applications as the act that initiates patent infringement in order to prevent generics from entering the market by taking risks. Indeed, both in Türkiye and in many EU countries, price, and reimbursement applications may be considered as an imminent threat of infringement or an offer for sale. Therefore, the broadening of this concept will prevent the effective and timely enforcement of patent rights.
According to the most recent European Commission report, Türkiye is still a key partner and candidate country for the European Union. Therefore, EU pharmaceutical legislation is closely monitored, and amendments are reflected in our legislation as appropriate, albeit, to a large extent. Recently, the processes of marketing authorisation and the placing on the market of medicinal products were harmonised with EU Directive 2001/83/EC, and the Regulation on Marketing Authorisation of Medicinal Products for Human Use was published in the Official Gazette on 11 December 2021 and entered into force. The amendments to EU legislation introduced by the Proposal are being negotiated by both the European Council and the European Parliament and should be closely monitored for implications for Türkiye.
Endnotes
1 https://www.efpia.eu/media/gy5j1nkt/efpia-recommendations-on-the-revision-of-the-pharmaceutical-package.pdf
2 https://www.ab.gov.tr/siteimages/resimler/T%C3%BCrkiye%20Report%202023.pdf
ICLG.com is a leading global platform for legal reference, analysis and news, hosting comprehensive comparative legal guides and research tools that cover law in more than 191 jurisdictions across 59 practice areas. ICLG.com also provides daily legal news and legal conference directories, as well as online purchasing of the renowned International Comparative Legal Guide series of print publications. https://iclg.com
Delivery Format:
HTML
Immediate Delivery
Access Rights | Content Availability: 
The content of this subscriber knowledge library area, the technology platform and tools are provided for information purposes only. No legal liability or other responsibility is accepted for any errors, omissions, or any loss, damage or inconvenience caused as a result of reliance on such information, or statements on this site, or any site to which these pages connect, since we cannot control the content or take responsibility for pages maintained by external providers. Where we provide links to sites, we do not by doing so endorse any information or opinions appearing in them. This courseware includes resources copyrighted and open educational resources (OER) by multiple individuals and organizations. If someone else is given access to your account login information, that person has read, understands and accepts the Conditions of Use for this platform.
Objectives and Study Scope
This study has assimilated knowledge and insight from business and subject-matter experts, and from a broad spectrum of market initiatives. Building on this research, the objectives of this market research report is to provide actionable intelligence on opportunities alongside the market size of various segments, as well as fact-based information on key factors influencing the market- growth drivers, industry-specific challenges and other critical issues in terms of detailed analysis and impact.
The report in its entirety provides a comprehensive overview of the current global condition, as well as notable opportunities and challenges.
The analysis reflects market size, latest trends, growth drivers, threats, opportunities, as well as key market segments. The study addresses market dynamics in several geographic segments along with market analysis for the current market environment and future scenario over the forecast period.
The report also segments the market into various categories based on the product, end user, application, type, and region.
The report also studies various growth drivers and restraints impacting the market, plus a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
This analysis also examines the competitive landscape within each market. Market factors are assessed by examining barriers to entry and market opportunities. Strategies adopted by key players including recent developments, new product launches, merger and acquisitions, and other insightful updates are provided.
Research Process & Methodology
We leverage extensive primary research, our contact database, knowledge of companies and industry relationships, patent and academic journal searches, and Institutes and University associate links to frame a strong visibility in the markets and technologies we cover.
We draw on available data sources and methods to profile developments. We use computerised data mining methods and analytical techniques, including cluster and regression modelling, to identify patterns from publicly available online information on enterprise web sites.
Historical, qualitative and quantitative information is obtained principally from confidential and proprietary sources, professional network, annual reports, investor relationship presentations, and expert interviews, about key factors, such as recent trends in industry performance and identify factors underlying those trends - drivers, restraints, opportunities, and challenges influencing the growth of the market, for both, the supply and demand sides.
In addition to our own desk research, various secondary sources, such as Hoovers, Dun & Bradstreet, Bloomberg BusinessWeek, Statista, are referred to identify key players in the industry, supply chain and market size, percentage shares, splits, and breakdowns into segments and subsegments with respect to individual growth trends, prospects, and contribution to the total market.
Research Portfolio Sources:
Global Business Reviews, Research Papers, Commentary & Strategy Reports
M&A and Risk Management | Regulation
The future outlook “forecast” is based on a set of statistical methods such as regression analysis, industry specific drivers as well as analyst evaluations, as well as analysis of the trends that influence economic outcomes and business decision making.
The Global Economic Model is covering the political environment, the macroeconomic environment, market opportunities, policy towards free enterprise and competition, policy towards foreign investment, foreign trade and exchange controls, taxes,
financing, the labour market and infrastructure.
We aim update our market forecast to include the latest market developments and trends.
Review of independent forecasts for the main macroeconomic variables by the following organizations provide a holistic overview of the range of alternative opinions:
As a result, the reported forecasts derive from different forecasters and may not represent the view of any one forecaster over the whole of the forecast period. These projections provide an indication of what is, in our view most likely to happen, not what it will definitely happen.
Short- and medium-term forecasts are based on a “demand-side” forecasting framework, under the assumption that supply adjusts to meet demand either directly through changes in output or through the depletion of inventories.
Long-term projections rely on a supply-side framework, in which output is determined by the availability of labour and capital equipment and the growth in productivity.
Long-term growth prospects, are impacted by factors including the workforce capabilities, the openness of the economy to trade, the legal framework, fiscal policy, the degree of government regulation.
Direct contribution to GDP
The method for calculating the direct contribution of an industry to GDP, is to measure its ‘gross value added’ (GVA); that is, to calculate the difference between the industry’s total pretax revenue and its total boughtin costs (costs excluding wages and salaries).
Forecasts of GDP growth: GDP = CN+IN+GS+NEX
GDP growth estimates take into account:
Market Quantification
All relevant markets are quantified utilizing revenue figures for the forecast period. The Compound Annual Growth Rate (CAGR) within each segment is used to measure growth and to extrapolate data when figures are not publicly available.
Revenues
Our market segments reflect major categories and subcategories of the global market, followed by an analysis of statistical data covering national spending and international trade relations and patterns. Market values reflect revenues paid by the final customer / end user to vendors and service providers either directly or through distribution channels, excluding VAT. Local currencies are converted to USD using the yearly average exchange rates of local currencies to the USD for the respective year as provided by the IMF World Economic Outlook Database.
Industry Life Cycle Market Phase
Market phase is determined using factors in the Industry Life Cycle model. The adapted market phase definitions are as follows:
The Global Economic Model
The Global Economic Model brings together macroeconomic and sectoral forecasts for quantifying the key relationships.
The model is a hybrid statistical model that uses macroeconomic variables and inter-industry linkages to forecast sectoral output. The model is used to forecast not just output, but prices, wages, employment and investment. The principal variables driving the industry model are the components of final demand, which directly or indirectly determine the demand facing each industry. However, other macroeconomic assumptions — in particular exchange rates, as well as world commodity prices — also enter into the equation, as well as other industry specific factors that have been or are expected to impact.
Forecasts of GDP growth per capita based on these factors can then be combined with demographic projections to give forecasts for overall GDP growth.
Wherever possible, publicly available data from official sources are used for the latest available year. Qualitative indicators are normalised (on the basis of: Normalised x = (x - Min(x)) / (Max(x) - Min(x)) where Min(x) and Max(x) are, the lowest and highest values for any given indicator respectively) and then aggregated across categories to enable an overall comparison. The normalised value is then transformed into a positive number on a scale of 0 to 100. The weighting assigned to each indicator can be changed to reflect different assumptions about their relative importance.
The principal explanatory variable in each industry’s output equation is the Total Demand variable, encompassing exogenous macroeconomic assumptions, consumer spending and investment, and intermediate demand for goods and services by sectors of the economy for use as inputs in the production of their own goods and services.
Elasticities
Elasticity measures the response of one economic variable to a change in another economic variable, whether the good or service is demanded as an input into a final product or whether it is the final product, and provides insight into the proportional impact of different economic actions and policy decisions.
Demand elasticities measure the change in the quantity demanded of a particular good or service as a result of changes to other economic variables, such as its own price, the price of competing or complementary goods and services, income levels, taxes.
Demand elasticities can be influenced by several factors. Each of these factors, along with the specific characteristics of the product, will interact to determine its overall responsiveness of demand to changes in prices and incomes.
The individual characteristics of a good or service will have an impact, but there are also a number of general factors that will typically affect the sensitivity of demand, such as the availability of substitutes, whereby the elasticity is typically higher the greater the number of available substitutes, as consumers can easily switch between different products.
The degree of necessity. Luxury products and habit forming ones, typically have a higher elasticity.
Proportion of the budget consumed by the item. Products that consume a large portion of the
consumer’s budget tend to have greater elasticity.
Elasticities tend to be greater over the long run because consumers have more time to adjust their behaviour.
Finally, if the product or service is an input into a final product then the price elasticity will depend on the price elasticity of the final product, its cost share in the production costs, and the availability of substitutes for that good or service.
Prices
Prices are also forecast using an input-output framework. Input costs have two components; labour costs are driven by wages, while intermediate costs are computed as an input-output weighted aggregate of input sectors’ prices. Employment is a function of output and real sectoral wages, that are forecast as a function of whole economy growth in wages. Investment is forecast as a function of output and aggregate level business investment.
APU Content Aggregation Service